Efficacy of Aurosling in Frontalis Sling Suspension Surgery
Launched by AUROLAB · Sep 16, 2008
Trial Information
Current as of September 08, 2025
Completed
Keywords
ClinConnect Summary
Silicon rod is an effective and safe material used in frontalis suspension in treating ptosis with poor levator function.The elasticity and ease of adjustment of silicon rod are ideal characteristics for suspension material used to treat severe ptosis in patients with poor bells phenomenon. In the present study , we attend to study the efficacy of aurosling silicon material as a suspension material for frontalis sling surgery
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Congenital Ptosis
- • Severe Ptosis (MRD\<0)
- • Poor levator function (\<4mm by Berke's method)
- • Myogenic Ptosis (Myasthenia gravis)
- • Chronic progressive external ophthalmoplegia
- • Neurogenic Ptosis (Third cranial palsy)
- • Blepharospasm
- • Ptosis caused by trauma
- Exclusion Criteria:
- • Acquired Ptosis
- • Horners syndrome
- • Blepharochalasis/Dermatochalasis
- • Mechanical Ptosis
- • Mild or Moderate Ptosis (MRD 1\>1)
- • Good or fair levator function (\>4 mm by Berke's method)
- • Previous Ptosis surgery
- • Ptosis associated syndromes/Other anomalies including
- • Marcus Gunn jaw winking syndrome
- • Blepharophimosis syndrome
- • Dry eye syndromes
- • Corneal anesthesia
- • Medical/Pediatric/Anesthesia condition contraindicating to surgery or anesthesia
- • Nystagmus where adequate measurements could not be done
- • Uncorrected vertical squint of any sort
About Aurolab
Aurolab is a leading global organization dedicated to advancing eye care through the development and manufacturing of innovative medical devices and pharmaceuticals. Based in India, Aurolab specializes in producing high-quality ophthalmic products, including intraocular lenses and surgical instruments, aimed at improving patient outcomes and accessibility to eye care solutions. Committed to research and development, Aurolab actively sponsors clinical trials to evaluate the safety and efficacy of its products, ensuring compliance with international standards and contributing to the global fight against blindness. Through collaboration with healthcare professionals and institutions, Aurolab strives to enhance vision health and promote sustainable eye care practices worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madurai, Tamil Nadu, India
Patients applied
Trial Officials
Usha Kim, DO, Dip NB
Principal Investigator
Aravind Eye Hospital, Madurai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials